98%
921
2 minutes
20
Background: Lichen sclerosus (LS) is a common autoimmune dermatological condition that is often under-diagnosed in women and has been documented to affect quality of life and sexual function.
Aim: To determine the prevalence of sexual dysfunction among women with vulvar lichen sclerosus.
Methods: The authors conducted a systematic review and meta-analysis of the existing research on LS and sexual function in database including PubMed using search terms: lichen sclerosus OR vulvar lichen sclerosus OR vulvar lichen sclerosus et atrophicus OR kraurosis vulvae) AND (sexual function OR sexual functions OR sexual disorder OR sexual disorders OR sexual activity OR sexual activities OR sexual dysfunction OR sexual dysfunctions OR dyspareunia OR vaginismus).
Outcomes: Nearly 60% of women with lichen sclerosus suffer from sexual dysfunction.
Results: Two hundred and ten studies were initially identified. Twenty-six articles met inclusion criteria and 3 were excluded as they did not relate to sexual function, were regarding a surgical or medical intervention and sexual dysfunction and one was a review article. Therefore, 23 studies were included in the final analysis resulting in a cumulative 486 participants with LS with 208 patients experiencing any kind of sexual dysfunction. Meta-analysis presented prevalence of sexual dysfunction among LS patients as 59% (95% CI: 48 - 70%). Dyspareunia or generalized pain with intercourse was the most commonly reported type of dysfunction.
Clinical Implications: Discussing sexual concerns with women with LS could empower them to seek treatment.
Strengths And Limitations: Few articles met criteria for inclusion.
Conclusion: A large proportion of women with LS experience sexual dysfunction. More research is needed, especially that which includes biopsy-proven LS and validated tools on sexual function. Pope R, Lee MH, Myers A, et al. Lichen Sclerosus and Sexual Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med 2022;19:1616-1624.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jsxm.2022.07.011 | DOI Listing |
Climacteric
September 2025
Obstetrics and Gynecology Department, Marmara University School of Medicine, Istanbul, Turkey.
Objective: This study aimed to investigate the association between the day-to-day impact of vaginal aging and female sexual function among postmenopausal Turkish women.
Method: The McCoy Female Sexuality Questionnaire (MFSQ) and the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire were distributed to 195 postmenopausal women. The most bothersome vulvovaginal symptoms were recorded.
Neuropsychiatr Dis Treat
September 2025
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Background: The benefits of phosphodiesterase-5 inhibitors in the treatment of sexual dysfunction and psychopathology of schizophrenia remain unclear. This systematic review and meta-analysis aimed to address the above clinical question.
Methods: Our primary outcome includes erectile dysfunction (ED) assessed using standardized questionnaires.
Encephale
September 2025
Psychiatry 'A' Department, Hedi Chaker University Hospital, Sfax, Tunisia.
Aims: Cannabis is widely used for various reasons, including its effects on sexuality. It has significant short- and long-term health consequences. However, its impact on sexual health remains uncertain.
View Article and Find Full Text PDFCuad Bioet
September 2025
Facultad de Farmacia y Nutrición de la Universidad de Navarra, Irunlarrea, 1, 31008 Pamplona.
In recent years, there has been a significant increase in minors with gender dysphoria (GD) seeking transition treatments, including puberty blockers and cross-sex hormones. The developing child's brain exhibits structural and functional differences in children with GD compared to cisgender children, particularly in areas where sex differences exist. Brain development during childhood and adolescence is strongly influenced by sex hormones.
View Article and Find Full Text PDFAndrology
September 2025
Department of Urology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
Background: Drug-induced hypogonadism is an underrecognized but significant adverse effect of various medications, contributing to male sexual dysfunction and infertility. Despite its clinical significance, comprehensive studies systematically identifying high-risk drugs remain limited.
Objectives: This study aimed to investigate the potential drugs associated with hypogonadism from FDA Adverse Event Reporting System.